• Volume 16,Issue 11,2017 Table of Contents
    Select All
    Display Type: |
    • >Clinical Research
    • Outcomes of renal function and risk factors in elderly patients with acute kidney injury:analysis of 652 cases

      2017, 16(11):801-806. DOI: 10.11915/j.issn.1671-5403.2017.11.187

      Abstract (1653) HTML (0) PDF 3.34 M (2085) Comment (0) Favorites

      Abstract:Objective To investigate the complete recovery rate of renal function, clinical characteristics and risk factors for non-recovery in the elderly with acute kidney injury (AKI), determine the effect of different causes on the short-term prognosis, and investigate the relationship of different stages of AKI with renal function recovery. Methods A retrospective cohort study was carried out on 652 elderly AKI patients (≥75 years old) who hospitalized in our geriatric wards from January 2007 to December 2015. After 90 days’ follow-up, these patients were divided into survival group and death group, and the former group was further assigned into recovery group and non-recovery group according to their renal function. Basic information, clinical data (diagnostic time, mean arterial pressure, urine volume, dialysis, mechanical ventilation, observation indicators and ratio of persistent AKI), AKI stages and causes were collected and analyzed. SPSS statistics 17.0 was used for data processing. Student’s t test, Mann-Whitney U test, Chi-sqaure test or Fisher’s exact test was used for comparison of different data types between groups. Multivariate logistic regression analysis (forward) was adopted to analyze the risk factors of renal function recovery. Results The median age of the 652 patients was 87(84 to 91) years. The mortality rate of the cohort was 33.6%(219/652). Among the 433 survivals, 316 patients (73%,316/433) got complete recovery in renal function, and the other 117 cases (27%, 117/433) did not recover. Infection, hypovolemia, cardiova-scular events, nephrotoxicity, and surgery were the common causes for hospital acquired AKI in the elderly. The incidence of infection (53.0% vs 33.0%; P<0.001) was significantly higher, while the ratio of using nephrotoxic drugs (5.5% vs 15.2%; P=0.001) was obviously lower in the death group than the survival group. For the survived patients, the recovery subgroup had higher ratio of diabetes mellitus, lower baseline serum creatinine (SCr), higher basal estimated glomerular filtration rate (eGFR) than the non-recovery subgroup (P<0.01). Furthermore, the recovery subgroup also had shorter time for diagnosis of AKI, lower peak level and SCr level at diagnosis, higher level of blood urea nitrogen (BUN), and lower ratios of dialysis requirement and persistent AKI (P<0.05). But there was no significant difference in AKI stage between the 2 subgroups (P>0.05). Multivariate logistic regression analysis showed that increased basal eGFR (OR=0.897,5%CI:0.842-0.956; P=0.001) was a protective factor for renal function recovery, while persistent AKI (OR=4.497,5%CI:2.774-7.290; P<0.001) was a risk factor for renal function recovery in elderly patients with AKI at 90 d after diagnosis. Conclusion Clinicians should identify the key causes influencing the prognosis of elderly AKI, that is, infection and application of nephrotoxic drugs, and concern about decreased basal eGFR and persistent AKI. What’s more, early detection and intervention may improve the prognosis of elderly AKI patients.

    • Risk factors for heart failure with preserved ejection fraction and its correlation with serum neprilysin in the elderly

      2017, 16(11):807-811. DOI: 10.11915/j.issn.1671-5403.2017.11.188

      Abstract (2224) HTML (0) PDF 2.83 M (1751) Comment (0) Favorites

      Abstract:Objective To determine the independent risk factors for chronic heart failure with preserved ejection fraction (HFpEF) in the elderly and investigate the correlation between HFpEF and serum neprilysin (NEP). Methods A total of 56 consecutive patients admitted in the cardiovascular ward of the healthcare center of our hospital from January 2014 to January 2017 were enrolled in this study. Thirty-one HFpEF patients served as HFpEF group. Another 25 non-heart failure patients who matched with the HFpEF group in age, gender, comorbidity and medication and hospitalized in the same period served as control group. Serum NEP level was tested in the 2 groups by enzyme-linked immunosorbent assay (ELISA), and the results and other parameters were compared between the 2 groups. SPSS statistics 16.0 was used to perform the statistical analysis. Data were analyzed by Student’s t test or Chi-square test as appropriate. Parametric and non-parametric test were performed by Pearson and Spearman correlation analysis, respectively. Binary stepwise backwards logistic regression analysis was carried out to assess the independent risk factors for HFpEF. Results Compared with control group, the HFpEF group had significantly higher serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level [(3857.7±618.7) vs (1960.3±331.4)ng/L, P=0.000], serum uric acid level [(363.34±147.56) vs (332.11±84.58)μmol/L,P=0.042], left atrial diameter [(44.29±7.34) vs (37.59±2.97)mm, P=0.007], and left ventricular end diastolic diameter [(54.43±8.41) vs (49.13±2.77)mm, P=0.013], while obviously lower serum NEP level [(0.82±0.33) vs (0.98±0.62)ng/ml, P=0.001]. Only NT-proBNP was the independent risk factor for HFpEF in this cohort (95%CI:1.000-1.004,P=0.037) after adjustment of the confounding variables. There was no correlations of serum NEP level with NT-proBNP level, NYHA class and echocardiographic parameters (all P>0.05). Conclusion NT-proBNP is an independent risk factor for HFpEF in the elderly. Serum NEP has no correlation with NT-proBNP, and shows limited predictive value for HFpEF.

    • Effects of hepatocyte growth factor and transforming growth factor-β1 on proli-feration of primarily cultured human atrial fibroblasts

      2017, 16(11):812-817. DOI: 10.11915/j.issn.1671-5403.2017.11.189

      Abstract (1709) HTML (0) PDF 3.73 M (1550) Comment (0) Favorites

      Abstract:Objective To investigate the role of hepatocyte growth factor (HGF) and transforming growth factor beta 1 (TGF-β1) on the proliferation of human atrial fibroblasts cultured in vitro, and determine the effect of HGF on the expression of TGF-β1 in human atrial fibroblasts. Methods A total of 20 patients with rheumatic heart disease (RHD) who underwent cardiac valve replacement in the Department of Cardiovascular Surgery of Fujian Provincial Hospital were recruited in this study. They were 10 cases of sinus rhythm (SR) and 10 cases of chronic atrial fibrillation (CAF), and were assigned into as SR group and CAF group accordingly. The data of left atrial diameter (LAD) were collected for each patient. After moderate right atrial appendage tissues were obtained during the operation, the atrial fibroblasts were isolated and primarily cultured. Then the obtained cells were treated with different concentrations of HGF (25,0, 100 and 200 ng/ml) and TGF-β1 (0.1,1, 10 and 100 ng/ml) for different times (12,4, 48 and 72 h), the effects of the concentrations and time periods on the proliferation of atrial fibroblasts were studied by water-soluble sulfonated tetrazolium (WST-1). The expression of TGF-β1 at mRNA level in atrial fibroblasts from the SR, CAF and HGF intervention group (the cells from CAF group after 100 ng/ml HGF treatment for 48 h) were analyzed with RT-PCR. SPSS statistics 19.0 was used for data processing. Student’s t test was used for the comparison between groups, and single factor analysis of variance was used for intergroup comparison. Results LAD was significantly larger in the CAF patients than the SR patients [(5.76±1.37) vs (4.43±0.77)cm]. HGF and TGF-β1 respectively inhibited and promoted the proliferation of human atrial fibroblasts in dose-dependent (rHGF=-0.686, rTGF-β1=0.655,P<0.05) and time-dependent manners (rHGF=0.557, rTGF-β1=0.840, P<0.05), with a peak action of 100 ng/ml HGF for 48 h, and of 10 ng/ml TGF-β1 for 48 h. TGF-β1 plus HGF showed inhibitory effect on cell proliferation. The mRNA expression level of TGF-β1 was decreased in both SR group (0.92±0.66) and HGF intervention group (0.67±0.64) when compared with CAF group (1.78±0.98, P<0.01). Conclusion The CAF patients have larger LAD and increased TGF-β1 expression. HGF inhibits TGF-β1 expression in human atrial fibroblasts, and partially counteracts the promoting role of TGF-β1 on cell proliferation.

    • Expression of adipocyte fatty acid-binding protein 4 in macrophages of elderly male patients with metabolic syndrome

      2017, 16(11):818-822. DOI: 10.11915/j.issn.1671-5403.2017.11.190

      Abstract (1816) HTML (0) PDF 2.84 M (1702) Comment (0) Favorites

      Abstract:Objective To investigate the expression of adipocyte fatty acid binding protein (FABP4) in the macrophages of elderly male patients with metabolic syndrome (MS). Methods A total of 108 elderly patients who were admitted in our hospital from January to October 2013 were enrolled in this study. According to being diagnosed as MS or not, they were divided into MS group (n=68) and non-MS group (n=40). Serum levels of interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) were detected by enzyme-linked immunosorbent assay (ELISA). And serum level of high-sensitivity C-reactive protein (hs-CRP) was measured by immunoturbidimetric assay. After the peripheral blood monocytes were obtained by Ficoll density gradient centrifugation and adherence method, the monocytes were differentiated to macrophages. The expression of FABP4 in the macrophages was determined by Western blotting. SPSS statistics 16.0 was used to analyze the data. According to data type, Students’ t test or Chi-square test were adopted. Correlation between indices was analyzed by Pearson linear correlation analysis. Results Compared with the non-MS group, the serum levels of IL-6 [(105.7±17.1) vs(135.4±11.8)pg/ml], TNF-α [(20.60±6.19) vs(29.50±5.74)pg/ml], hs-CRP [(1.98±1.00) vs(3.54±1.12)mg/L] and VEGF [(130.8±19.9) vs(180.2±48.1)pg/ml], as well as the expression of FABP4 [(0.25±0.13) vs(0.36±0.10)] in the macrophages were significantly higher in the MS group (P<0.05). Correlation analysis showed that the FABP4 was positively correlated with VEGF (r=0.536), IL-6 (r=0.369), TNF-α (r=0.441), and hs-CRP (r=0.597, all P<0.05). Conclusion The protein level of FABP4 in the peripheral blood macrophages is high in the elderly male MS patients. FABP4 may be involved in the incidence and development of vascular endothelial impairments in MS patients, and the mechanism may be related to the inflammatory reaction and vascular endothelial dysfunction.

    • Clinical study of pituitrin in treatment of gut-derived septic shock

      2017, 16(11):823-826. DOI: 10.11915/j.issn.1671-5403.2017.11.191

      Abstract (2022) HTML (0) PDF 2.30 M (1705) Comment (0) Favorites

      Abstract:Objective To analyze the clinical value of pituitrin in treatment of the patients with gut-derived septic shock. MethodsA prospective randomized controlled trial was conducted on the patients with gut-derived septic shock admitted to the Intensive Care Unit of our hospital from June 2013 to March 2017. The enrolled 64 patients were randomized into routine treatment group and pituitrin treatment group. According to the International Sepsis Treatment Guideline in 2012, the patients of the routine treatment group were given 50 ml normal saline containing 3 mg norepinephrine, while those from the pituitrin treatment group were given 24 U pituitrin and 48 ml normal saline through deep venous catheter. Heart rate (HR), mean arterial pressure (MAP), intra-abdominal pressure (IAP), dosage of norepinephrine, white blood cell count (WBC), platelet count (PLT), lactic acid (Lac), total bilirubin (TBIL), serum creatinine (SCr), fasting blood glucose (FBG), oxygen index (OI), acute physiology and chronic health evaluation system Ⅱ (APACHE Ⅱ) score and sequential organ failure assessment score (SOFA) at admission and 24 h after treatment were measured, and the mortality within 28 d was observed. The quantitative data were expressed as mean±standard deviation ([AKx-D]±s). The comparison between groups was conducted with Student’s t test, and that among groups was analyzed with univariate variance analysis. Enumeration data were expressed as percentage, and inter-group comparison was carried out with Chi-square test or Fisher’s exact test. ResultsThere were no significant differences in HR, MAP, IAP, WBC, PLT, Lac, TBIL, SCr, FBG, OI, dosage of norepinephrine, APACHE Ⅱ score and SOFA score before the treatment between the 2 groups (P>0.05). Compared with the baseline data, the routine treatment group had increased HR and the dosage of norepinephrine, but decreased WBC, FBG and SOFA score, while the pituitrin treatment group had reduced HR, IAP, WBC, FBG, Lac, dosage of norepinephrine and SOFA score in 24 h after treatment (P<0.05). The decreases of HR, Lac, IAP and dosage of norepinephrine were more significant in the pituitrin treatment group than the routine treatment group (P<0.05), and the former group had higher OI, though without obvious difference (P=0.066). The mortality rates within 28 d were 46.66% and 35.29% respectively in the routine treatment group and the pituitrin treatment group (P=0.355). Conclusion Combined injection of pituitrin can reduce the dosage of norepinephrine, slow HR down, decrease IAP and Lac level in the patients with gut-derived septic shock. The agent shows better clinical value for the patients.

    • Different doses of atorvastatin for the elderly patients receiving coronary stent implantation:a 12-month follow-up study

      2017, 16(11):827-831. DOI: 10.11915/j.issn.1671-5403.2017.11.192

      Abstract (2155) HTML (0) PDF 2.82 M (1669) Comment (0) Favorites

      Abstract:Objective To investigate the efficacy of different dose of atorvastatin in the elderly patients receiving coronary stent implantation. Methods A total of 237 elderly patients with coronary heart disease who underwent coronary stent implantation for the first time in our department from July 2014 to April 2015 were enrolled in this study. These patients were randomly assigned into intensive dose group (n=119,0 mg, once per day, for 12 months) and sequential dose group (n=118,0 mg, once per day, for 1 month, then 20 mg, once per day, for another 11 months). In 1 month after implantation, liver and kidney functions, blood lipids, blood glucose and other indicators were detected, then blood lipids test, echocardiography and coronary angiography were performed in 11 months later, and the incidences of major adverse cardiovascular events (MACEs) were recorded during follow-up. SPSS statistics 17.0 was used to perform the statistical analysis. Student’s t test and Chi-square test were employed for comparison of different data types between groups. Results In 1 and 12 months after implantation, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) were significantly decreased in the both groups when compared with the baseline values (P<0.05). At the latter time point, the intensive dose group had obviously lower TG and LDL-C, but higher ejection fraction (EF) than the sequential dose group (P<0.05). During the follow-up period, there was no abnormal liver function, muscle pain, or freshly-diagnosed diabetes in the 2 groups, and no significant difference was found in the incidence of MACEs (P>0.05). Coronary angiography indicated that there was no difference in the occurrence of late lumen loss or restenosis between the 2 groups (P>0.05). Conclusion The efficacy of sequential dose of atorvastatin is similar as that of intensive dose in the elderly coronary stent implantation.

    • Detection of serum 25-hydroxy vitamin D3 level in patients with chronic heart failure and its significance

      2017, 16(11):832-836. DOI: 10.11915/j.issn.1671-5403.2017.11.193

      Abstract (1718) HTML (0) PDF 3.01 M (1907) Comment (0) Favorites

      Abstract:Objective To investigate the correlation of serum level of 25-hydroxy vitamin D3 (25(OH)D3) with the severity of heart failure, and evaluate its clinical value. Methods A total of 152 patients who met the diagnostic criteria of 2014 Chinese Heart Failure Diagnosis and Treatment Guidelines were recruited in this study. They were 78 males and 74 females, at an age of (72.7±12.7)years, and according to the results of the New York Heart Association (NYHA) Functional Classification, they were assigned into NYHA-Ⅰ group (group A, n=44), NYHA-Ⅱ group (group B, n=51) and NYHA-Ⅲ-Ⅳ group (group C, n=57). After serum 25(OH)D3 level and other biochemical indices were detected, the differences in the 3 groups and the correlations of the serum 25(OH)D3 level with the severity of chronic heart failure were analyzed. All the data were analyzed by SPSS statistics 19.0, and Student’s t test, analysis of variance, least significant difference (LSD) test and Chi-square test were adopted for intergroup comparison. Linear regression analysis was employed to analyze the correlation of the 25(OH)D3 level with heart failure. Results There were significant differences in brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) and hemoglobin (Hb) in the 3 groups (P<0.05). The 25(OH)D3 level was (22.53±8.17), (18.13±6.69) and (14.55±6.09)ng/ml respectively in the groups A, B and C, and significant difference was seen among them (P<0.05). The results of LSD test showed that the level of 25(OH)D3 was significantly higher in group A than in group B and group C (P<0.05). The linear regression correlation analysis indicated that the level was negatively correlated with BNP and age (P=0.000, P=0.002), but positively with LVEF (P=0.000). Conclusion 25(OH)D3 level is negatively correlated with the severity of chronic heart failure. But whether vitamin D supplementation is beneficial to alleviating symptoms and improving prognosis needs further large-scale study.

    • Efficacy of amikacin combined with cefoperazone/sulbactam in the elderly patients with chronic heart failure and pulmonary infection

      2017, 16(11):837-840. DOI: 10.11915/j.issn.1671-5403.2017.11.194

      Abstract (2023) HTML (0) PDF 2.24 M (1809) Comment (0) Favorites

      Abstract:Objective To investigate the efficacy of amikacin combined with cefoperazone/sulbactam in the treatment of chronic heart failure (CHF) and pulmonary infection in the elderly. Methods A total of 100 patients with CHF and pulmonary infection admitted in our hospital from January 2009 to December 2016 were enrolled in this study. According to the random number table, the patients were divided into control group and observation group (n=50). The control group was given intravenous infusion of cefoperazone/sulbactam. The observation group received intravenous infusion of cefoperazone/sulbactam plus amikacin. After the treatment course of 7-14 d, the respiratory rate, heart rate, partial pressure of arterial carbon dioxide (PaCO2) and oxygen (PaO2), time to symptom relief, efficacy and bacterial clearance were compared between the 2 groups. SPSS statistics 20.0 was used for statistical analysis. According to the data type, Student’s t test and Chi-square test were used to make comparison between the 2 groups. ResultsCompared with before treatment, the respiratory rate, heart rate, PaCO2 and PaO2 were significantly improved in both groups (P<0.05). After the treatment, the observation group had significantly reduced respiratory rate, heart rate and PaCO2, and obviously elevated PaO2 when compared with the control group (P<0.05). The time periods to reliefs of moist rale [(4.3±1.2) vs (6.0±2.1)d], asthma [(2.2±1.4) vs (3.5±1.7)d], cough [(5.2±1.3) vs (7.4±1.8)d], and high fever [(2.4±1.1) vs (3.5±1.2) d] were notably shorter in the observation group than the control group (P<0.05). What’s more, the observation group had remarkably higher efficacy (94.0% vs 76.0%) and bacterial clearance (71.4% vs 47.4%) than the control group (P<0.05). ConclusionAmikacin combined with cefoperazone/sulbactam is superior to cefoperazone/sulbactam in the treatment of the elderly with CHF and pulmonary infection.

    • Prognostic impact of different waiting times for elective PCI in non-infarct-related arteries in patients with ST-segment elevation myocardial infarction

      2017, 16(11):841-845. DOI: 10.11915/j.issn.1671-5403.2017.11.195

      Abstract (1777) HTML (0) PDF 2.76 M (1605) Comment (0) Favorites

      Abstract:Objective To investigate the effect of different waiting times of elective percutaneous coronary intervention (PCI) for non-infarct related artery (Non-IRA) on the prognosis in patients with ST segment elevation myocardial infarction (STEMI). MethodsA retrospective study was carried out on 160 STEMI patients with multivessel disease hospitalized in our department from August 2015 to December 2016. They were 105 males and 55 females, at an age of(63.1±9.6)years. According the waiting times for elective PCI, they were assigned into ≤14 d group (n=92) and 30-60 d group (n=68). The results of coronary angiography, numbers of Non-IRA stent implantation and the main complications during hospitalization were compared. The patients were followed up for 6 months. The incidence of major adverse cardiovascular events (MACEs) were compared between the 2 groups in 1 and 6 months after PCI. The differences between the groups were compared by Student’s t test and Chi-square test for different data types. ResultsThere was no significant difference in the implanted stent number between the ≤14 d group and 30-60 d group (P>0.05). The incidence of PCI related complications during hospitalization was obvious higher in the ≤14 d group than the 30-60 d group (18.5% vs 7.4%; P=0.43). There was no obvious difference in the incidence of MACEs in 1 month after PCI between the 2 groups, but the incidence was notably lower in the 30-60 d group in 6 months (5.9% vs 16.3%;P=0.042). Conclusion Waiting time of 30-60 d reduces the risks for PCI-related complications during hospitalization and for MACEs in 6 months after PCI, and which might be an optional time for elective PCI in treatment of Non-IRA.

    • Antiplatelet and prognostic effects of ticagrelor and clopidogrel in diabetes patients with acute coronary syndrome after percutaneous coronary intervention

      2017, 16(11):846-849. DOI: 10.11915/j.issn.1671-5403.2017.11.196

      Abstract (2039) HTML (0) PDF 2.24 M (1697) Comment (0) Favorites

      Abstract:Objective To evaluate the antiplatelet efficacy of clopidogrel and ticagrelor in the patients with acute coronary syndrome (ACS) and diabetes mellitus after percutaneous coronary intervention (PCI), and investigate the effect on prognosis by thrombelasto-graphy. Methods A total of 100 patients with ACS and diabetes admitted in our department from June 2016 to January 2017 were prospectively enrolled in this study. They were randomized into clopidolgrel group and ticagrelor group (n=50). Thrombelastography was carried out in 24 to 48 h after PCI for inhibitory effects on arachidonic acid (AA)-induced platelet aggregation, adenosine diphosphate (ADP)-induced platelet aggregation and maximum ADP (MAADP). The incidences of major adverse cardiovascular events (MACE), bleeding events and dyspnea were compared between the 2 groups during the follow-up of 6 months after PCI. SPSS statistics 19.0 was used for data processing. Students’ t test or Chi-square test were adopted for comparison of different data types between groups. Results The patients of ticagrelor group had significantly higher inhibition rates in AA pathway [(72.3±26.6)% vs (54.0±31.4)%, P=0.041] and in ADP pathway [(76.5±22.1)% vs (43.4±28.7)%, P=0.016], but obviously lower MAADP [(33.2±10.5) vs (48.2±13.6)mm, P=0.024] when compared with the clopidogrel group. The patients with AA inhibition rate <50% (14.0% vs 38.0%; P=0.006) and ADP inhibition rate <30% (6.0% vs 28.0%; P=0.003) were notably fewer in the tigcagrelor group than the clopidogrel group. There were no significant differences in the incidences of MACE and dyspnea between the 2 groups. Conclusion Ticagrelor is superior to clopidolgrel in antiplatelet effect in the diabetes patients with ACS after PCI.

    • Changes of serum high-sensitivity C-reactive protein, retinol-binding protein 4 and plasma haptoglobin levels in patients with coronary heart disease and its significance

      2017, 16(11):850-853. DOI: 10.11915/j.issn.1671-5403.2017.11.197

      Abstract (1874) HTML (0) PDF 2.36 M (1978) Comment (0) Favorites

      Abstract:Objective To investigate the serum levels of high-sensitivity C-reactive protein (hs-CRP) and retinol-binding protein 4 (RBP4) and plasma level of haptoglobin (Hp) in the patients with coronary heart disease (CHD) and their clinical significance. Methods A total of 140 CHD patients diagnosed by coronary angiography in our department from February 2014 to February 2017 were recruited in this study, and assigned into CHD group. Another 60 patients hospitalized due to non-CHD in our department during the same period were assigned as control group. According to the clinical manifestations, the patients in the CHD group were further divided into 3 subgroups:acute myocardial infarction (AMI) group (n=38), unstable angina pectoris (UAP) group (n=62) and stable angina pectoris (n=40). And they were also assigned into single-vessel disease group (n=27), double-vessel disease group (n=54) and triple-vessel disease group (n=59) according to the number of involved vessels. Gensini score, serum levels of hs-CRP and RBP4, and plasma level of Hp were evaluated and detected respectively. The relationship of these indices with the severity of CHD was analyzed. SPSS statistics 16.0 was used for data processing. Student’s t test or Chi-square test were adopted for comparison of different data types between groups. Correlation between indices was analyzed by Pearson linear correlation analysis. Results The CHD group had significantly higher serum levels of hs-CRP[(7.29±3.65) vs (2.84±1.16))mg/L], RBP4 [(49.64±8.32) vs (42.07±5.51) ng/ml] and plasma level of Hp [(95.26±19.14) vs (70.13±16.33) mg/L] than the control group (P<0.05). The serum levels of hs-CRP and RBP4, Gensini score and plasma Hp level were significantly higher in the AMI patients than the SAP and UAP patients (P<0.05). So were in the UAPpatients than the SAP patients (P<0.05). The triple-vessel disease subgroup also had higher above indices than the double-vessel disease subgroup (P<0.05), and such trends were also seen between the double-vessel and single-vessel disease subgroups (P<0.05). Gensini score of the CHD patients were positively correlated with serum levels of hs-CRP (r=0.619) ,RBP4 (r=0.554), and plasma Hp level (r=0.592, all P<0.05). Conclusion The CHD patients have obviously higher serum levels of hs-CRP, RBP4 and plasma level of Hp, which are significantly related to the severity of coronary lesions.

    • >Clinicopathological Conference
    • One case of Castleman’s disease with fever, renal injury and lymphadenectasis as main manifestations

      2017, 16(11):856-858. DOI: 10.11915/j.issn.1671-5403.2017.11.199

      Abstract (1823) HTML (0) PDF 1.86 M (2037) Comment (0) Favorites

      Abstract:Due to untypical manifestations, missed diagnosis and misdiagnosis of Castleman’s disease are very common in clinical practice. It is essential to grasp its clinicopathological characteristics to reduce missed diagnosis and misdiagnosis. In this paper, we reported one patient with clinical manifestations of fever, kidney injury and lymphadenectasis. After admission, the patient was finally diagnosed as Castleman’s disease with pathological finding, combined with clinical manifestations and laboratory results. We expect that this report will promote the understanding and diagnosis of the disease for clinicians.

    • >Review
    • Research progress on mechanism of acute high-altitude illness

      2017, 16(11):859-862. DOI: 10.11915/j.issn.1671-5403.2017.11.200

      Abstract (1826) HTML (0) PDF 2.19 M (2887) Comment (0) Favorites

      Abstract:High altitude environment is characterized by hypobaric hypoxia, low temperature and intense solar radiation. Among them, the most prominent one is hypoxia, and it can influence healthy individuals in many aspects. Acute high-altitude illness refers to acute mountain sickness (AMS), high-altitude cerebral edema (HACE) and high-altitude pulmonary edema (HAPE) which people may suffer from when ascending to an altitude level of over 2500 m. With more and more people having the demand into the plateau areas, the pathogenesis, prevention and treatment of acute high-altitude illness have received more attention. In present, the pathogenesis of the disease remains unclear, and thus little progress has been made in its pharmacologic prevention and treatment. In this article, we summarized the possible mechanisms of the illness in order to provide new targets for its prevention and treatment.

    • Mechanism and progress of new drugs for treatment of diabetes in intervention of Alzheimer’s disease

      2017, 16(11):863-867. DOI: 10.11915/j.issn.1671-5403.2017.11.201

      Abstract (1890) HTML (0) PDF 2.69 M (1938) Comment (0) Favorites

      Abstract:Type 2 diabetes mellitus (T2DM) is proven to have some similarities in etiology and pathophysiology with Alzheimer’s disease (AD). In recent years, evidence also has suggested that some new drugs for diabetes, such as glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase 4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitor, have some effects on the central nervous system. These findings provide new strategy for AD treatment, that is, using these diabetes drugs for intervention of AD. In this paper, we reviewed the pathophysiological characteristics of AD, the correlation between AD and T2DM, and the application of GLP-1, DPP-4 inhibitor and SGLT2 inhibitor in the intervention of AD.

    • Progress on mechanism and toxicity of Tripterygium wilfordii in treatment of diabetic nephropathy

      2017, 16(11):868-872. DOI: 10.11915/j.issn.1671-5403.2017.11.202

      Abstract (1550) HTML (0) PDF 2.69 M (2062) Comment (0) Favorites

      Abstract:Diabetic kidney disease (DKD) is a serious microvascular complication of diabetes mellitus, and it has high mortality and disability and poor outcome after treatment. The pathogenesis of DKD remains unknown, but the effect of inflammatory reactions in its incidence and development cannot be ignored. Tripterygium wilfordii Hook.f. possesses special anti-inflammatory and anti-immune effects, but exerts mild effect on blood glucose. Therefore, it is widely used in treatment of DKD in recent years, and also becomes a hot spot in clinical study. This article reviewed the mechanism and toxicity of Tripterygium wilfordii Hook.f. in treatment of DKD in aspects of immunosuppression, inhibition of inflammatory cell infiltration and cytokine expression, improvement of oxidative stress, and protection of podocytes.

    • Research progress of inflamm-aging and osteoporosis

      2017, 16(11):873-876. DOI: 10.11915/j.issn.1671-5403.2017.11.203

      Abstract (1714) HTML (0) PDF 2.05 M (2483) Comment (0) Favorites

      Abstract:Inflamma-aging refers to the chronic proinflammatory state of the body that appears in the process of aging and progre-ssively with aging. Osteoporosis is a systemic disorder of bone metabolism, which is characterized by low bone mineral content, bone microstructure damage, reduced bone strength, increased bone fragility, and easy fracture. At present, some prospective studies abroad have found that inflamm-aging is closely related to osteoporosis. In this paper, we reviewed the research progress on the concept and mechanism of inflamm-aging, and on the relationship between inflamm-aging and osteoporosis.

    • Research progress on role of secreted protein acidic and rich in cysteine (SPARC) in lung cancer and pulmonary fibrosis

      2017, 16(11):877-880. DOI: 10.11915/j.issn.1671-5403.2017.11.204

      Abstract (1887) HTML (0) PDF 2.28 M (1736) Comment (0) Favorites

      Abstract:Secreted protein acidic and rich in cysteine (SPARC) governs fundamental cellular functions such as cell adhesion, proliferation and differentiation, and also regulates the expression and activities of numerous growth factors and matrix metalloproteinases (MMPs) which are essential for degradation and turnover of extracellular matrix (ECM). In the lung,SPARC drives pathological responses in non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF) by promoting microvascular remodeling and excessive deposition of ECM proteins. However, the role of SPARC in chronic airway conditions, such as asthma and chronic obstructive pulmonary disease (COPD), has far been overlooked. This article reviewed current progress of its role in NSCLC and IPF, and highlighted its effect in chronic airway diseases such as asthma and COPD.

Superintendor:Chinese PLA General Hospital

Sponsor:Medical Innovation Research Division, Chinese PLA General Hospital/ National Clinical Research Center for Geriatric Diseases (Chinese PLA General Hospital)/Department of Cardiology, Sixth Medical Center, Chinese PLA General Hospital

Editor-in-Chief:Fan Li

Executive Editor:Chen Yundai

Tel:010-66936756

E-mail: zhlndqg@mode301.cn

ISSN:1671-5403

CN:11-4786/R

Founding Date:2002

Publishing Cycle:Monthly

Postal Code:82-408

  • Most Read
  • Most Cited
  • Most Downloaded
Press search
Search term
From To